An open-label, single-dose, randomized, 4-period, crossover, bioequivalence study of three new formulations of premarin 0.45mg/medroxyprogesterone acetate (MPA) 1.5mg [conjugated estrogens/medroxyprogesterone] compared with a reference formulation of premarin/MPA (Prempro) 0.45mg/1.5mg in healthy postmenopausal women

Trial Profile

An open-label, single-dose, randomized, 4-period, crossover, bioequivalence study of three new formulations of premarin 0.45mg/medroxyprogesterone acetate (MPA) 1.5mg [conjugated estrogens/medroxyprogesterone] compared with a reference formulation of premarin/MPA (Prempro) 0.45mg/1.5mg in healthy postmenopausal women

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2007

At a glance

  • Drugs Conjugated estrogens/medroxyprogesterone (Primary)
  • Indications Menopausal syndrome; Osteoporosis
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 19 Jun 2007 Status changed from recruiting to in progress
    • 12 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top